Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

NCT07630961 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
HR+/HER2- Ductal Breast Cancer (BC)
HR+/HER2- Lobular Breast Cancer (BC)
Triple Negative Breast Cancer (TNBC)
Colorectal Cancer (CRC)
Soft Tissue Sarcoma (STS)

Interventions

DRUG: 68Ga-DFC413
DRUG: 68Ga-NNS309

Sponsor

Novartis Pharmaceuticals